Development
The neuroinflammation-synaptic dysfunction hypothesis posits that certain aspects of this pathophysiology progression axis are amenable to therapeutic intervention. For example, activation of kinase activity in the endogenous brain immune cells called glia can increase levels of proinflammatory cytokines that, if not regulated, can result in neuronal dysfunction. Altered protein kinase activity in neurons can bring about neuronal dysfunctions that can be detected by glia, which results in further stimulation of an evolving stress cycle. The progressive pathophysiology is eventually evidenced by altered brain and cognitive function. Serine/threonine protein kinases are logical yet under utilized potential therapeutic targets for the neuroinflammation-synaptic dysfunction axis.
MW150 is a lead asset currently in the clinical trial stage of development. MW150 is a unique and orally bioavailable p38alphaMAPK inhibitor that exhibits brain exposure and efficacy in diverse disease models. The models include tauopathies, Alzheimer's disease and related dementia, and neuropsychiatric disorders characterized by neuroinflammation and synaptic dysfunction. There are no approved drugs or drugs at clinical trial stage with MW150's unique profile of molecular recognition, pharmacological selectivity and robust intellectual property position. MW150 is potentially a new therapeutic intervention mechanism for neurologic disease modification and has potential as an co-therapy with drugs that exhibit complementary mechanisms.
Other assets are at preclinical drug development or discovery phase.
MW150 is a lead asset currently in the clinical trial stage of development. MW150 is a unique and orally bioavailable p38alphaMAPK inhibitor that exhibits brain exposure and efficacy in diverse disease models. The models include tauopathies, Alzheimer's disease and related dementia, and neuropsychiatric disorders characterized by neuroinflammation and synaptic dysfunction. There are no approved drugs or drugs at clinical trial stage with MW150's unique profile of molecular recognition, pharmacological selectivity and robust intellectual property position. MW150 is potentially a new therapeutic intervention mechanism for neurologic disease modification and has potential as an co-therapy with drugs that exhibit complementary mechanisms.
Other assets are at preclinical drug development or discovery phase.